Despite the fact that biotech share values were heading south at the beginning of the second quarter of 2014, the short-lived negative environment failed to scare off investors completely, with companies maintaining the momentum built from the first quarter, as far as raising cash is concerned. Read More
Deal flow for initial public offerings (IPOs) could be on pace to break the record number of offerings completed way back in 2000 at the height of the genomics boom. So far 44 global IPOs have climbed through the open window and, as of June 30, a further 37 were waiting in the wings. For those private companies not quite ready for IPO prime time, generating funding hasn't been a problem either, with more than $3 billion raised year to date, 73 percent more than the total raised at the same point last year. Read More
